Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, FOG Pharmaceuticals dba FogPharma is raising $177,999,922.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Gregory Verdine played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About FOG Pharmaceuticals dba FogPharma
FogPharma is developing a new class of drugs to address the limitations of todays precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.

To learn more about FOG Pharmaceuticals dba FogPharma, visit http://fogpharma.com/

Contact:
Gregory Verdine, President and Chief Executive Officer
617-945-9510
https://www.linkedin.com/in/greg-verdine-b181991/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved